Carvedilol Versus Placebo for Treatment in Post Traumatic Stress Disorder (PTSD)

• Status: Unknown status
• Trial end date: 2011-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators hypothesize that carvedilol, at less then therapeutic doses for cardiac effect, will reduce symptoms of Post Traumatic Stress Disorder.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Columbia Northwest Pharmaceuticals
• Treatments: Carvedilol

Criteria

Inclusion Criteria:

• Diagnosis of Post Traumatic Stress Disorder according to DSM-IV

• Must be able to speak, read and understand the English language and be able to provide written informed consent

Exclusion Criteria:

• current, unstable and significant medical condition/illness

• bronchial asthma or related bronchospastic condition

• AV block

• Sick Sinus Syndrome

• Bradycardia

• Peripheral hear disease

• Unstable thyroid disorder

• History of seizure disorder

• Females who are pregnant, lactating or planning to become pregnant

• Bipolar

• Schizophrenia

• Dementia

• Intolerance or hypersensitivity to alpha or beta blockers